Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed COO
Pharma-Bio Serv, Inc. (PBSV) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/31/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2023 8-K Quarterly results
Docs: "DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2023 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year. Net income for the quarter ended January 31, 2023 was approximately $0.4 million, an increase of approximately $0.1 million when compared to the same period last year. "This quarter we were able to successfully maximize our resources in more profitable markets. This strategy yielded a positive effect on our overall g..."
03/17/2023 10-Q Quarterly Report for the period ended January 31, 2023
03/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "DORADO, PUERTO RICO / ACCESSWIRE / March 1, 2023 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about April 14, 2023 to shareholders of record at the close of business on March 29, 2023. Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life scie..."
02/09/2023 8-K Quarterly results
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Pharma-Bio Serv Retains Investment Banking Firm ACP Capital to Provide Investment Banking and M&A Advisory Services DORADO, PUERTO RICO / ACCESSWIRE / February 7, 2023 / Pharma-Bio Serv, Inc. , a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, announced today that it has retained ACP Capital Markets LLC for investment banking and M&A advisory services. ACP Capital Markets is a specialized investment bank focused on capital markets and advisory assignments. ACP’s capital markets unit specializes in private equity and debt placements while its M&A and Advisory practice is globally focused, covering both public and private marke..."
01/30/2023 8-K Quarterly results
Docs: "DORADO, PUERTO RICO / ACCESSWIRE / January 30, 2023 / Pharma-Bio Serv, Inc. , is a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries. Today, Pharma-Bio Serv announced that revenues for the year ended October 31, 2022 were approximately $19.4 million, a decrease of approximately $0.7 million when compared to last year. Additionally, net income for the year ended October 31, 2022 was approximately $1.0 million, an improvement of approximately $3.0 million when compared to last year. The net income variance is mostly due to the recording of an account receivable provision of approximately $5.2 million in 2021 which was partially of..."
01/30/2023 10-K Annual Report for the period ended October 31, 2022
09/14/2022 8-K Quarterly results
Docs: "DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2022 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm providing services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2022 were approximately $4.8 and $14.8 million, respectively. This represents a decrease of approximately $0.2 million and an increase of $0.2 million, for three and nine months respectively, when compared to the same periods last year. Net income for the three and nine months ended July 31, 2022 was approximately $0.3 and $0.8 million, respectively, a decrease for both periods of approximately $2.0 million when compared to the sa..."
09/14/2022 10-Q Quarterly Report for the period ended July 31, 2022
06/24/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
06/14/2022 10-Q Quarterly Report for the period ended April 30, 2022
05/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2022 8-K Quarterly results
Docs: "DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2022 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2022 were approximately $5.0 million, an increase of approximately $0.5 million when compared to the same period last year. Net income for the quarter ended January 31, 2022 was approximately $0.3 million, reflecting no significant change when compared to the same period last year. “Our efforts to diversify and expand our geographical revenue should be noted in this quarter’s results. The continental US and Europe consulting markets represen..."
03/17/2022 10-Q Quarterly Report for the period ended January 31, 2022
02/28/2022 10-K/A Annual Report for the period ended October 31, 2021 [amend]
02/14/2022 8-K Quarterly results
Docs: "Pharma-Bio Serv Announces Full Year Results and Declares a Special Dividend"
02/11/2022 10-K Annual Report for the period ended October 31, 2021
02/01/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
11/15/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Pharma-Bio Serv Announces Special Dividend November 15, 2021 DORADO, PUERTO RICO / ACCESSWIRE / November 15, 2021 / Pharma-Bio Serv, Inc. , a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for Shareholders. The Special Dividend will be payable on or about January 3, 2022 to shareholders of record at the close of business on December 15, 2021. Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting relat..."
09/27/2021 8-K Other Events  Interactive Data
09/14/2021 8-K Quarterly results
09/14/2021 10-Q Quarterly Report for the period ended July 31, 2021
06/25/2021 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/14/2021 8-K Quarterly results
06/14/2021 10-Q Quarterly Report for the period ended April 30, 2021
06/03/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
05/03/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2021 8-K Quarterly results
03/17/2021 10-Q Quarterly Report for the period ended January 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy